Search

Your search keyword '"Takeshi YOSHIKAWA"' showing total 7 results
Start Over Author "Takeshi YOSHIKAWA" Database Supplemental Index
7 results on '"Takeshi YOSHIKAWA"'

1. Electrochemical ammonia oxidation catalyzed by ruthenium complexes: investigation of substituent effect of axial pyridine ligands.

Author

Hiroki Toda, Ryoichi Kanega, Tasuku Yano, Takeshi Yoshikawa, Shogo Kuriyama, Yuichiro Himeda, Ken Sakata, and Yoshiaki Nishibayashi

Abstract

We have examined catalytic ammonia oxidation using ruthenium complexes bearing 2,2'-bipyridine-6,6'-dicarboxylate ligand and axial 3- and 4-substituted pyridine ligands under electrochemical conditions to study the substituent effect of the axial pyridine ligands. Ruthenium complex bearing 3,4-dibromopyridine ligands shows the highest catalytic activity to produce up to 145 equivalents of dinitrogen based on the catalyst. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Synthesis of (Silico)aluminophosphate Molecular Sieves Using an Alkanolamine as a Novel Organic Structure-directing Agent.

Author

Xiying Li, Watcharop Chaikittisilp, Zhendong Liu, Yutaka Yanaba, Takeshi Yoshikawa, Torn Wakihara, and Tatsuya Okubo

Abstract

An alkanolamine, N,N,N',N'-tetrakis(2-hydroxyethyl)ethyl-enediamine, is used as an organic structure-directing agent (OSDA) to synthesize aluminophosphate (AlPO-5) and silico- aluminophosphate (SAPO-5 and -34) molecular sieves. The phase selectivity among them is feasible by optimizing experimental conditions wherein high concentrations of OSDA and silicon source favor the formation of SAPO-34. In addition, the phase selectivity between SAPO-5 and SAPO-34 is examined in detail by altering the chemical compositions of the raw materials. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

7. A Randomized Phase II/III Study of R-THP-Cop Vs R-CHOP for Patients Younger Than 70 Years with DLBCL

Author

Goto, Naoe, Matsumoto, Takuro, Shibata, Yuhei, Kitagawa, Junichi, Kanemura, Nobuhiro, Takeshi, Yoshikawa, Kasahara, Senji, Goto, Hideko, Fukuno, Kenji, Hara, Takeshi, Yamada, Toshiki, Sawada, Michio, Takahashi, Takeshi, Saito, Koshiro, Moriwaki, Hisataka, and Tsurumi, Hisashi

Abstract

Introduction: Since the introduction of rituximab (R), a prognosis of diffuse large B cell lymphoma (DLBCL) is markedly improved. The rituximab-CHOP (R-CHOP) regimen, consisting of R, cyclophosphamide (CPA), doxorubicin (DXR), vincristine (VCR), and prednisolone (PSL), has become the current standard treatment for patients with DLBCL. On the other hand, the cardiotoxic problem due to DXR still remains. Pirarubicin (tetrahydropyranyl adriamycin: THP), a derivative of DXR, was reportedly an anthracyclin with less cardiotoxicity than DXR. Before introduction of rituximab, we reported the equivalent result between CHOP and THP-COP using THP instead of DXR regimen in aggressive non-Hodgkin’s lymphomas (74% of enrolled patients were DLBCL) (Tsurumi H et al. J Cancer Res Clin Oncol. 2004). In addition, we reported the efficacy and safety of R-THP-COP regimen for DLBCL in phase II study (Hara T et al. J Cancer Res Clin Oncol. 2010). Here, we prospectively compared the efficacy and safety of R-THP-COP and R-CHOP regimens as a clinical trial in Gifu Hematology Study Group.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results